Management of Resistant Hypertension Without Calcium Channel Blockers

Introduction to Guideline-Directed Therapy

• The European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines recommend beta-blockers as acceptable alternatives in three-drug combinations when standard options are not suitable 1.
• The 2024 ESC guidelines suggest beta-blockers be combined with other major blood pressure-lowering drug classes when there are compelling indications or when standard combinations cannot be used 2, 3.

Rationale for Beta-Blocker Use

• Beta-blockers have demonstrated effectiveness in reducing cardiovascular events, particularly in patients with coronary artery disease, post-myocardial infarction, or heart failure 4, 5.
• Beta-blockers work through different mechanisms than ACE inhibitors and thiazides, providing additive blood pressure lowering through heart rate reduction, decreased cardiac output, and reduced renin release 1.

Consideration of Mineralocorticoid Receptor Antagonists

• The American Diabetes Association and ESC guidelines recommend mineralocorticoid receptor antagonists for patients not meeting blood pressure targets on three classes of medications including a diuretic 6, 7, 8, 2, 3.
• Mineralocorticoid receptor antagonists are particularly effective when added to existing ACE inhibitor/ARB, thiazide, and calcium channel blocker therapy, with additional cardiovascular and renal benefits 6, 8.
• Serum creatinine and potassium must be monitored regularly due to increased hyperkalemia risk when combining with ACE inhibitors 6, 7, 8.

Clinical Decision Making

• If the patient has resistant hypertension, consider adding spironolactone 25mg daily, monitoring potassium closely 6, 8, 2.
• If the patient does not have resistant hypertension, add a beta-blocker as the third agent, selecting based on patient characteristics such as cardioselective beta-blockers for hypertension management 1, 2.
• Avoid beta-blockers in patients with severe bradycardia, heart block, or decompensated heart failure 4.

Critical Considerations

• Do not add an ARB to the existing ACE inhibitor, as dual RAS blockade increases adverse events without additional benefit 6, 7, 8, 2.
• Do not use alpha-blockers as preferred third-line agents, as they were inferior to chlorthalidone for heart failure prevention in ALLHAT 4, 5.
• Ensure the patient's current medications, benazepril and chlorthalidone, are at maximally tolerated doses before adding a third agent 9, 6, 7.